Humedix Co., Ltd.

KOSDAQ 200670.KQ

Humedix Co., Ltd. EPS (Diluted) for the year ending December 31, 2023: USD 1.93

Humedix Co., Ltd. EPS (Diluted) is USD 1.93 for the year ending December 31, 2023, a 7.40% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Humedix Co., Ltd. EPS (Diluted) for the year ending December 31, 2022 was USD 1.80, a 122.63% change year over year.
Humedix Co., Ltd. EPS (Diluted) for the year ending December 31, 2021 was USD 0.81, a -44.62% change year over year.
Humedix Co., Ltd. EPS (Diluted) for the year ending December 31, 2020 was USD 1.46, a 54.52% change year over year.
Humedix Co., Ltd. EPS (Diluted) for the year ending December 31, 2019 was USD 0.94, a 9.49% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

KOSDAQ: 200670.KQ

Humedix Co., Ltd.

CEO	Jin-hwan Kim
IPO Date	Dec. 26, 2014
Location	South Korea
Headquarters	603, 268, Hagui-ro
Employees	226
Sector	Health Care
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies

Description

Humedix Co., Ltd., a healthcare company, researches, develops, manufactures, and sells various pharmaceutical products in South Korea. It offers over-the-counter drugs, prescription medicines, active pharmaceutical ingredients, medical devices, cosmetic products, and functional synthetic materials, as well as health functional foods. The company was formerly known as HVLS Co., Ltd. and changed its name to Humedix Co., Ltd. in 2010. The company was founded in 2002 and is headquartered in Anyang-si, South Korea.

Key trends

Past 5 years